10-Q: Intorio, Corp. Reports Q2 Results: Name Change and New Leadership Focus on Functional Medicine

Intorio, Corp. files its Form 10-Q for the quarter ended August 31, 2024, revealing a net loss and a shift in business direction under new leadership, focusing on functional medicine.

Summary

• Intorio, Corp. filed its Form 10-Q for the quarter ended August 31, 2024.
• The company reported a net loss of $12,944 for the three months ended August 31, 2024, and $14,862 for the six months ended August 31, 2024.
• Revenue for the three months ended August 31, 2024, was $0, compared to $750 for the same period in 2023.
• The company's accumulated deficit as of August 31, 2024, was $92,005.
• There was a change in control on May 16, 2024, with a new CEO and a shift in business focus towards functional medicine.
• The company plans to change its name to REDOX International Group.
• The company's disclosure controls and procedures were deemed not effective as of August 31, 2024.
• The company states it will need to raise additional funds in the next twelve months in order to sustain and expand its operations.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's losses, lack of revenue, going concern uncertainty, and ineffective disclosure controls, despite the potential of the new business direction.

Positives

• The company has a new CEO with extensive experience in functional medicine.
• The company is shifting its focus to the functional medicine market, which could present growth opportunities.
• A loan from a shareholder of $54,160 was converted to equity, improving the company's balance sheet.

Negatives

• The company reported a net loss of $12,944 for the three months ended August 31, 2024.
• Revenue for the three months ended August 31, 2024, was $0.
• The company has an accumulated deficit of $92,005 as of August 31, 2024.
• The company's disclosure controls and procedures were deemed not effective as of August 31, 2024.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company needs to raise additional capital to fund its operations.
• The company's disclosure controls and procedures are not effective.
• The company has no employees other than its officer and director.
• The company has a limited operating history and a history of losses.

Future Outlook

The company expects working capital requirements to be funded through existing funds and further issuances of securities, with requirements expected to increase in line with business growth; existing capital, advances, debt instruments, and anticipated cash flow are expected to fund operations over the next three months.

Management Comments

• Management plans to obtain additional capital resources by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking third party equity and/or debt financing.
• Management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

Industry Context

The company is shifting its focus to functional medicine, a growing area within healthcare that emphasizes personalized and preventative approaches. This move aligns with increasing consumer interest in holistic wellness and alternative therapies.

Comparison to Industry Standards

• It is difficult to compare Intorio, Corp.'s results to industry standards due to its early stage and shift in business focus.
• Companies in the functional medicine space often focus on recurring revenue models through subscriptions or long-term patient care programs.
• Key competitors in the functional medicine laboratory testing space include companies such as Genova Diagnostics and Doctor's Data, which have established reputations and broader testing menus.

Management Changes

Legal Proceedings

• Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties.

Related Party Transactions

• From inception through May 16, 2024, the Company previous sole officer and director loaned the Company $ 54,160 to pay for incorporation costs and operating expenses.
• On October 18, 2024, and October 21, 2024, a related party provided the Company with loans of $2,525 and $5,000, respectively, to cover operating expenses.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• Employees (currently only the CEO) are impacted by the company's financial instability.
• Customers may be affected by the shift in business focus and potential changes in service offerings.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• The company plans to change its name to REDOX International Group.
• The company intends to finance expenses with further issuances of securities and debt issuances.
• The company will seek to obtain short-term loans from its directors.

Key Dates

Keywords

functional medicine, REDOX International Group, net loss, Form 10-Q, Intorio Corp, financial results, going concern, capital raise, Han-Wen Ou, change of control